


Specimen Instructions

FoundationOne®CDx is an extensively validated tissue-based comprehensive genomic profiling service for all solid tumours. FoundationOne CDx analyses 324 cancer-related genes to provide potentially actionable information to help guide treatment options.¹⁻³



Acceptable Samples

- Formalin-fixed paraffin embedded (FFPE) specimens, including cut slide specimens are acceptable.
- Use standard fixation methods to preserve nucleic acid integrity. 10% neutral-buffered formalin for 6–72 hours is industry standard. DO NOT use other fixatives (Bouins, B5, AZF, Holland's).
- Do not decalcify.



TUMOUR CONTENT

3

Optimum: 30% TN Minimum: 20% TN

Percent tumour nuclei (%TN) = number of tumour cells divided by total number of all cells with nuclei. Note for liver specimens: higher tumour content may be required because hepatocyte nuclei have twice the DNA content of other somatic nuclei.

Shipping Instructions

- Please place the samples, FoundationOne CDx Test Requisition Form, and any other documeths into the FoundationOne CDx Specimen Shipping Kit.
- 2. Please take out the Customs Invoice and Import Permit documents inside the FoundationOne CDx kit and place the FoundationOne CDx shipment kit that includes the sample and Test Requisition Form inside the provided shipment envelope (please seal the envelope prior shipment). Contact your Roche Foundation Medicine contact person to schedule the sample pick-up.
- 3. Please print the shipment labels (Airwaybill) and hold them together with all Customs Invoice and Import Permit documents, ready outside the shipment envelope (will be provided via email after requesting the sample pick-up).
- 4. Please wait for the driver to pick up the sample by handing over the sealed envelope and all shipment documents.

Intended Use

FoundationOne[®]CDx is a next generation sequencing based in vitro diagnostic device for detection of substitutions, insertion and deletion alterations (indels) and copy number alterations (CNAs) in 324 genes and select gene rearrangements, as well as genomic signatures including tumour mutational burden (TMB) and microsatellite instability (MSI) using DNA isolated from formalin-fixed paraffin embedded (FFPE) tumour tissue specimens. The test is intended as a companion diagnostic to identify patients who may benefit from treatment with therapies in accordance with the approved therapeutic product labeling. Additionally, FoundationOne CDx is intended to provide tumour mutation profiling to be used by qualified health care professionals in accordance with professional guidelines in oncology for patients with solid malignant neoplasms. For full information on the intended use, assay descriptions, and for detailed performance specifications, refer to the complete FoundationOne CDx label at rochefoundationmedicine.com

References

- 1. FoundationOne*CDx FDA Approval, 2017. Available at: https://www.accessdata.fda.gov/cdrh_docs/pdf17/P170019a.pdf (Accessed August 2018).
- FoundationOne*CDx FDA Approval Press Release, 2017. Available at: https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm587273.htm (Accessed August 2018).
- 3. FoundationOne*CDx Technical Specifications 2018. Available at: www.rochefoundationmedicine.com/f1cdxtech.

Foundation Medicine^{*} and FoundationOne^{*} are registered trademarks of Foundation Medicine, Inc. Roche is the licensed distributor of Foundation Medicine products outside of the United States. Email: europe.foundationmedicine@roche.com / Phone: +49 7624 14 2098 PR/FMI/1808/0015 | Date of preparation: September 2018 FI/FMI/1810/0076



